TVRD Earnings & Financial Statements
Tvardi Therapeutics, Inc.
$1.06
-$0.04(-3.64%)
30
Overall
60
Value
9
Tech
21
Quality
Market Cap
$14.67M
Volume
58.06K
52W Range
$0.93 - $43.65
Target Price
$9.25
TVRD earnings and financial statements: Tvardi Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TVRD Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $7.14M | $20.97M | $41.87M | $23.03M |
| Cost of revenue | - | $620.0K | $6.17M | $7.27M | - |
| Operating income | -$26.75M | -$28.11M | -$121.50M | -$87.53M | -$89.08M |
| EBITDA | -$18.12M | -$29.30M | -$116.18M | -$83.80M | -$86.03M |
| Net income | -$18.21M | -$29.40M | -$118.51M | -$85.47M | -$88.44M |
| EPS (diluted) | $-3.26 | $-46.59 | $-6.57 | $-4.77 | $-5.22 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $32.07M | $35.20M | $125.84M | $182.24M | $247.06M |
| Total liabilities | $11.13M | $40.83M | $68.76M | $23.46M | $19.53M |
| Shareholders’ equity | $20.95M | -$91.13M | $57.09M | $158.78M | $227.52M |
| Cash and equivalents | $20.70M | $31.61M | $51.77M | $63.74M | $13.45M |
| Long-term debt | $85.0K | $30.46M | $6.09M | - | $1.92M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$23.50M | -$18.30M | -$21.04M | -$17.87M | -$60.09M |
| Capital expenditure | - | -$1.05M | - | -$50.0K | $31.0K |
| Free cash flow | -$23.50M | -$18.30M | -$21.04M | -$17.92M | -$60.06M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TVRD | $1.06 | -3.6% | 58.06K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Tvardi Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW